\
&
Contact us
\
&
Contact us
Published on | 2 months ago
Programmes ERCArticle 40 of the Digital Services Act (DSA) allows researchers to request data from very large online platforms and search engines (full list here) to study ‘systemic risks’ in the European Union. Systemic risks, as outlined in Article 34(1), include issues amplified or generated by such platforms, like the spread of disinformation, its effects on democratic processes, cyberbullying, online harassment, harmful content exposure, and the impact on minors’ physical and mental well-being, among others.
Under a new Delegated Act, researchers can submit applications for previously undisclosed or under-disclosed data access to national authorities - Digital Services Coordinators (DSCs). The impact of this new legal provision could be extensive, and open new avenues for research.
Within this context, the European Research Council Executive Agency (ERCEA) is reaching out to researchers conducting research on ‘systemic risks’ (ERC grantees or not). The ERCEA is planning a number of activities related to the DSA Art. 40 – such as the organisation of a small workshop on 22-23 October (with a web streamed part) and the production of relevant information material for researchers.
Researchers interested in this topic are invited to fill in this short survey.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space AI Continent Cybersecurity
The European Commission has opened a call for evidence to collect research and best practices on how to simplify its legislation, especially when it comes to data, cybersecurity and artificial intelligence (AI). This initiative is part of the Commission’s simplification agenda and efforts to create a more favourable business environment, by... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
